GLASGOW, SCOTLAND - (NewMediaWire) - June 1, 2016 - - HCi Viocare (OTCQB: VICA) (BERLIN;WKN#A2AG73; ISIN#US40416H2058), is pleased to announce that its wholly owned subsidiary HCi Viocare Technologies, the company behind the Smart Insole that monitors diabetic and athlete's feet, has developed a new application for its revolutionary sensing technology Flexisense™, now for automotive tires. Flexisense™ applied to the automotive sector brings vehicle users the future of the ultimate driving experience.

Flexisense™ applied to tires is able to monitor in real time tire deformation and actual traction between the tire and the ground, feeding back information to the vehicle's CPU, allowing the vehicle to adjust to varying road and weather conditions, and significantly increasing safety and performance. The system also provides actual power output data which can be used to improve engine and fuel efficiency, monitor tires and suspension life and improve driving experience.

The uniqueness of Flexisense™ consists of its affordability, its ability to work under any conditions such as heat, humidity and vibrations that negatively impact other sensing methods, and its incomparable flexibility and adaptability to different applications. The high interest shown by prospective partners for the Company's technology after its initial success with the diabetic insole drove HCi Viocare Technologies to develop further applications for athletic shoes, mattresses, bicycles, gaming, and now for the automotive industry and vehicle tires. 

Dr. Christos Kapatos, HCi Viocare's co-founder and CTO, stated, "We believe the adaptations of Flexisense™ are limitless -- our latest revolutionary project brings innovation to the automotive sector, as the driver and the vehicle receive useful information from the tires that make driving much easier and safer. A new era of driving experience has begun and our unique technology applied to tires is certainly a part of it."

About HCi Viocare

HCi Viocare (OTCQB: VICA);  BERLIN;WKN#A2AG73; ISIN#US40416H2058), has a dual, complementary business model of 1) creating the first cross-border independent chain of Prosthetics & Orthotics (P&O) and Diabetic Foot clinics in Europe and the Middle East and 2) developing a wide portfolio of proprietary hardware solutions with first in line the Flexisense™ sensor system, aiming to empower the user by providing on demand information in the fields of Digital Health, Prosthetics, Orthotics, Diabetes, Assistive Devices, Sports and Wellbeing, and licensing to established industry participants. HCi Viocare is listed on the OTC Markets in the USA, has its executive office in Athens, Greece and R&D center in Glasgow, UK. 

Please visit: www.hciviocare.com http://flexisense.hciviocare.com/

Forward Looking Statements

This press release contains forward-looking statements. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as "expects", "intends", "estimates", "projects", "anticipates", "believes", "could", and other similar words. All statements addressing product performance, events, or developments that the Company expects or anticipates will occur in the future are forward-looking statements, including but not limited to future developments in the areas of athletic shoes and the information and performance of the company's technology in such applications. Because the statements are forward-looking, they should be evaluated in light of important risk factors and uncertainties, some of which are described in the Company's Quarterly, Annual and Current Reports filed with the United States Securities and Exchange Commission (the "SEC"). Should one or more of these risks or uncertainties materialize, or should any of the Company's underlying assumptions prove correct, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on Company's forward-looking statements. In particular, the Company has acquired its first operational Prosthetics & Orthotics (P&O) clinic and is continuing development efforts for its other biomedical technologies, including a "smart insole" and its Flexisense TM sensing technology with several potential applications. There is no assurance that the Company will be successful in its ongoing expansion and development efforts, or that it will find suitable commercialization partners for its technologies. Except as required by law, HCi Viocare disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. No stock exchange, securities commission or other regulatory body has reviewed nor accepts responsibility for the adequacy or accuracy of this release. Investors are advised to carefully review the reports and documents that HCi Viocare files from time to time with the SEC, including its Annual, Quarterly and Current Reports.